Calcium Dobesilate After Radiofrequency Ablation for Varicose Veins
Not yet recruitingPhase 4NCT07390097
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study evaluates whether calcium dobesilate, a venoactive drug, improves recovery after radiofrequency ablation (RFA) for varicose veins. Patients with great saphenous vein insufficiency undergoing RFA will be randomly assigned to receive either calcium dobesilate (500 mg twice daily) or standard care alone. The treatment starts 7 days before the procedure and continues for 30 days after. The primary outcome is postoperative pain at day 7. Secondary outcomes include pain at days 14 and 30, quality of life, ecchymosis, and return to daily activities.
Study details
- Official title
- Effect of Perioperative Calcium Dobesilate on Postprocedural Pain, Symptom Relief, and Quality of Life After Radiofrequency Ablation for Great Saphenous Vein Insufficiency: A Randomized Controlled Trial
- Conditions
- Varicose Veins Leg
- Great Saphenous Vein Insufficiency
- Chronic Venous Insufficiency
- Interventions
- Drug: calcium dobesilate
- Sponsor
- Oguz Arslanturk
- Organization
- Bulent Ecevit University
- Start date
- 2026-02-28
- Primary completion
- 2026-08
- Sex
- All
- Age range
- from 18 Years to 70 Years
- Results posted
- No results posted in this snapshot
- Countries
- Turkey (Türkiye)
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Age 18-70 years * Symptomatic primary varicose veins (CEAP classification C2-C4) * Great saphenous vein insufficiency confirmed by duplex ultrasound (reflux \>0.5 seconds) * Great saphenous vein diameter 5-12 mm * Scheduled for radiofrequency ablation * Able to provide written informed consent Exclusion Criteria: * History of deep vein thrombosis * Peripheral arterial disease (ABI \<0.9) * Active venous ulcer (CEAP C6) * Pregnancy or breastfeeding * Severe renal or hepatic insufficiency * Known allergy to calcium dobesilate * Use of venoactive drugs within the past 4 weeks * Current anticoagulant therapy * Previous venous intervention on the same limb * Bilateral disease requiring simultaneous treatment * Inability to comply with follow-up schedule
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07390097